KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Operating Leases (2019 - 2025)

Opko Health (OPK) has disclosed Operating Leases for 7 consecutive years, with $36.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 24.64% year-over-year to $36.8 million, compared with a TTM value of $36.8 million through Dec 2025, down 24.64%, and an annual FY2025 reading of $36.8 million, down 24.64% over the prior year.
  • Operating Leases was $36.8 million for Q4 2025 at Opko Health, up from $36.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $61.2 million in Q2 2024 and bottomed at $28.0 million in Q4 2022.
  • Average Operating Leases over 5 years is $40.6 million, with a median of $36.5 million recorded in 2025.
  • The sharpest move saw Operating Leases surged 93.61% in 2023, then tumbled 39.11% in 2025.
  • Year by year, Operating Leases stood at $33.1 million in 2021, then fell by 15.51% to $28.0 million in 2022, then surged by 93.61% to $54.1 million in 2023, then dropped by 9.77% to $48.8 million in 2024, then fell by 24.64% to $36.8 million in 2025.
  • Business Quant data shows Operating Leases for OPK at $36.8 million in Q4 2025, $36.3 million in Q3 2025, and $37.3 million in Q2 2025.